Rituxan Comes In Like A Lion With Two New Indications
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA clears Genentech/Biogen Idec’s oncologic Rituxan for rheumatoid arthritis weeks after it was approved for first-line non-Hodgkins lymphoma.
You may also be interested in...
Genentech/Biogen Idec Position Rituxan To Compete Against Anti-TNFs In RA
In Phase III study, treatment with rituximab demonstrated a benefit in biologic-naive patients.
Genentech/Biogen Idec Position Rituxan To Compete Against Anti-TNFs In RA
In Phase III study, treatment with rituximab demonstrated a benefit in biologic-naive patients.
Dr. Reddy's Launches Rituxan Generic
Dr. Reddy's Laboratories launched the first follow-on biologic of the non-Hodgkin's lymphoma treatment rituximab on April 30, the company announced